Loading…
Apnimed, Inc.
Apnimed, Inc. (APMD) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Cambridge, United States and has 81 employees. The company is worth $739.36M and trades at 2.5x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $38.47M in fiscal 2025, up 380.1% from the year before. It reported a net loss of $932K. The share price is 49.7% below its 52-week high of $35.29. None of the 38 superinvestors we track reported it in their latest 13F. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in APMD.
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OBXObsidian Therapeutics, Inc. | $11.77 | — | — | 0.00% | — | $727.07M |
| GERNGeron Corp | $1.13 | — | 3.3x | 0.00% | -28.28% | $725.99M |
| ANNXAnnexon, Inc. | $3.81 | — | 3.6x | 0.00% | -105.26% | $722.3M |
| COLLCollegium Pharmaceutical Inc | $23.50 |
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
1 methods answered, across 1 families.
Room for errors in the reported numbers.
+887.3% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 18.1x |
| 2.4x |
| 0.00% |
| 17.61% |
| $765.06M |
| ANLAdlai Nortye Group Ltd. | $11.03 | — | 3.3x | 0.00% | -20.23% | $710.31M |
| SANASana Biotechnology, Inc. | $2.37 | — | 4.6x | 0.00% | -152.87% | $709.48M |